Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 6th ranked industry out of 145 stock market industries

Ticker	Company	Zen Rating	Value	Growth	Momentum	Sentiment	Safety	Financials	AI	1w Zen Rating	1m Zen Rating	3m Zen Rating	1y Zen Rating
GSK	GSK PLC	A	B	B	B	B	B	C	B	A	A	A	–
AMGN	AMGEN INC	A	B	C	C	B	C	A	C	A	A	C	C
GRFS	GRIFOLS SA	A	A	B	C	C	C	C	C	A	A	B	–
BMY	BRISTOL MYERS SQUIBB CO	A	A	B	C	C	B	B	C	A	A	A	A
SNY	SANOFI	A	A	C	C	C	C	B	B	B	B	B	–

Upgrade to Premium to View More

Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More

Already have access to Premium?

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Feb 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: B, Financials: C, and AI: B.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -3 points lower than the general drug manufacturer industry average of 39. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 52.84% over the past year, overperforming other general drug manufacturer stocks by 29 percentage points.

2. Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amgen (NASDAQ:AMGN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Amgen (NASDAQ:AMGN) has a Due Diligence Score of 49, which is 10 points higher than the general drug manufacturer industry average of 39.

AMGN passed 17 out of 38 due diligence checks and has strong fundamentals. Amgen has seen its stock return 17.21% over the past year, underperforming other general drug manufacturer stocks by -7 percentage points.

Amgen has an average 1 year price target of $330.91, a downside of -2.27% from Amgen's current stock price of $338.59.

Amgen stock has a consensus Hold recommendation according to Wall Street analysts. Of the 11 analysts covering Amgen, 18.18% have issued a Strong Buy rating, 9.09% have issued a Buy, 63.64% have issued a hold, while 9.09% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: C, and AI: C.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 38, which is -1 points lower than the general drug manufacturer industry average of 39. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 14 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 42.3% over the past year, overperforming other general drug manufacturer stocks by 18 percentage points.

Grifols Sa has an average 1 year price target of $10.00, an upside of 6.16% from Grifols Sa's current stock price of $9.42.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.66%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.74%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

2. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 4.25%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.74%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 3.34%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.74%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 83.5% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.71% in the last day, and down -1.2% over the last week. Pfizer was the among the top losers in the drug manufacturers - general industry, dropping -3.34% yesterday.

Pfizer shares are trading lower. The company reported Q4 financial results.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -46.34% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -71 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 24.18% in the past year. It has performed in line with other stocks in the general drug manufacturer industry.

3. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 18 points higher than the general drug manufacturer industry average of 39. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has gained 16.08% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -8 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 6.36% over the next year.

31.58% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 42.11% of general drug manufacturer stocks are rated B (Buy), 15.79% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 44.38x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.